Stock Track | CSPC PHARMA Soars 5% on Exclusive Licensing Agreement with Jiangsu Alphamab

Stock Track

Sep 30, 2024

CSPC Pharmaceutical Group Ltd saw its shares surge over 5% on Monday after announcing an exclusive licensing agreement with Jiangsu Alphamab for the development and commercialization of a novel cancer drug candidate in mainland China.

Under the agreement, CSPC PHARMA has secured the rights to develop and commercialize JSKN003, a potential best-in-class antibody-drug conjugate targeting HER2-positive solid tumors. In addition to an upfront payment, Jiangsu Alphamab will also receive milestone payments and royalties on any future sales of the drug in China.

Investors appear to be excited about the deal, which will bolster CSPC PHARMA's oncology pipeline with a promising new therapeutic candidate. JSKN003 has shown promising efficacy and safety data in early clinical trials, and the market for HER2-targeted drugs in China is expected to grow significantly in the coming years.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1129135602"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1129135602\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1129135602?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-30 11:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129135602","market":"us","top_or_hot":-1,"title":"Stock Track | CSPC PHARMA Soars 5% on Exclusive Licensing Agreement with Jiangsu Alphamab","media":"Stock Track","content":"<p>CSPC Pharmaceutical Group Ltd saw its shares surge over 5% on Monday after announcing an exclusive licensing agreement with Jiangsu Alphamab for the development and commercialization of a novel cancer drug candidate in mainland China.</p>\n\n<p>Under the agreement, CSPC PHARMA has secured the rights to develop and commercialize JSKN003, a potential best-in-class antibody-drug conjugate targeting HER2-positive solid tumors. In addition to an upfront payment, Jiangsu Alphamab will also receive milestone payments and royalties on any future sales of the drug in China.</p>\n\n<p>Investors appear to be excited about the deal, which will bolster CSPC PHARMA's oncology pipeline with a promising new therapeutic candidate. JSKN003 has shown promising efficacy and safety data in early clinical trials, and the market for HER2-targeted drugs in China is expected to grow significantly in the coming years.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CSPC PHARMA Soars 5% on Exclusive Licensing Agreement with Jiangsu Alphamab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CSPC PHARMA Soars 5% on Exclusive Licensing Agreement with Jiangsu Alphamab\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-09-30 11:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Ltd saw its shares surge over 5% on Monday after announcing an exclusive licensing agreement with Jiangsu Alphamab for the development and commercialization of a novel cancer drug candidate in mainland China.</p>\n\n<p>Under the agreement, CSPC PHARMA has secured the rights to develop and commercialize JSKN003, a potential best-in-class antibody-drug conjugate targeting HER2-positive solid tumors. In addition to an upfront payment, Jiangsu Alphamab will also receive milestone payments and royalties on any future sales of the drug in China.</p>\n\n<p>Investors appear to be excited about the deal, which will bolster CSPC PHARMA's oncology pipeline with a promising new therapeutic candidate. JSKN003 has shown promising efficacy and safety data in early clinical trials, and the market for HER2-targeted drugs in China is expected to grow significantly in the coming years.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1129135602","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129135602","pubTimestamp":1727667533,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CSPC Pharmaceutical Group Ltd saw its shares surge over 5% on Monday after announcing an exclusive licensing agreement with Jiangsu Alphamab for the development and commercialization of a novel cancer drug candidate in mainland China.Under the agreement, CSPC PHARMA has secured the rights to develop and commercialize JSKN003, a potential best-in-class antibody-drug conjugate targeting HER2-positive solid tumors. In addition to an upfront payment, Jiangsu Alphamab will also receive milestone paym","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"股票赛道石药集团因与江苏康宁杰瑞达成独家许可协议而飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group Ltd saw its shares surge over 5% on Monday after announcing an exclusive licensing agreement with Jiangsu Alphamab for the development and commercialization of a novel cancer drug candidate in mainland China.\nUnder the agreement, CSPC PHARMA has secured the rights to develop and commercialize JSKN003, a potential best-in-class antibody-drug conjugate targeting HER2-positive solid tumors. In addition to an upfront payment, Jiangsu Alphamab will also receive milestone payments and royalties on any future sales of the drug in China.\nInvestors appear to be excited about the deal, which will bolster CSPC PHARMA's oncology pipeline with a promising new therapeutic candidate. JSKN003 has shown promising efficacy and safety data in early clinical trials, and the market for HER2-targeted drugs in China is expected to grow significantly in the coming years.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}